Related references
Note: Only part of the references are listed.Second cancers in MPN: Survival analysis from an international study
Monia Marchetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Distinct modes of TNF signaling through its two receptors in health and disease
Kamar-Sulu N. Atretkhany et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy
Mrinmoy Das et al.
CELL DEATH & DISEASE (2020)
Role of inflammation in the biology of myeloproliferative neoplasms
Steffen Koschmieder et al.
BLOOD REVIEWS (2020)
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets
Bethan Psaila et al.
MOLECULAR CELL (2020)
Selective Targeting of TNF Receptors as a Novel Therapeutic Approach
Roman Fischer et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
Xiaosheng Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN
Jonas Samuel Jutzi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants
Elena Masselli et al.
CELLS (2020)
SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA
Subbaiah Chary Nimmagadda et al.
HAEMATOLOGICA (2019)
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
Simona Stivala et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
Daniel A. C. Fisher et al.
LEUKEMIA (2019)
Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice
Qian Xu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Tiziano Barbui et al.
LEUKEMIA (2019)
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms
Laura F. Mendez Luque et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Lucia Masarova et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP
Janin Knop et al.
CELL DEATH & DISEASE (2019)
Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm
Hew Yeng Lai et al.
BLOOD ADVANCES (2019)
Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
William L. Heaton et al.
LEUKEMIA (2018)
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
Yingjie Nie et al.
SCIENCE SIGNALING (2018)
Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Sergio Ferreira Cristina et al.
SEMINARS IN HEMATOLOGY (2018)
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
Yingjie Nie et al.
SCIENCE SIGNALING (2018)
Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells
Olga Ticha et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dysregulated iron metabolism in polycythemia vera: etiology and consequences
Yelena Z. Ginzburg et al.
LEUKEMIA (2018)
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
Sarah K. Williams et al.
SCIENTIFIC REPORTS (2018)
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner
Hadjer Abdelouahab et al.
ONCOTARGET (2017)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Tina M. Schnoeder et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
TNFR1 and TNFR2 differentially mediate TNF-α-induced inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes
Hongfeng Zhang et al.
CELL BIOLOGY INTERNATIONAL (2017)
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2016)
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
George D. Kalliolias et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
S. Koschmieder et al.
LEUKEMIA (2016)
Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice
Florian Kaelble et al.
PLOS ONE (2016)
Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration
Yun Dong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
Daria Sollazzo et al.
ONCOTARGET (2016)
C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients
Xiaoli Wang et al.
EXPERIMENTAL HEMATOLOGY (2015)
Pathogenesis of myeloproliferative neoplasms
Radek C. Skoda et al.
EXPERIMENTAL HEMATOLOGY (2015)
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hans Carl Hasselbalch et al.
MEDIATORS OF INFLAMMATION (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Emmanuel Pourcelot et al.
EXPERIMENTAL HEMATOLOGY (2014)
Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation
Katia De Filippo et al.
BLOOD (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
Rakhee Vaidya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Angela G. Fleischman et al.
BLOOD (2011)
Intravenous immunoglobulin G (IVIG) inhibits IL-1-and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration
Andrew C. Issekutz et al.
CLINICAL IMMUNOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
TNF receptor 2 pathway: drug target for autoimmune diseases
Denise Faustman et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study
PH Reitsma et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
vavCre transgenic mice:: A tool for mutagenesis in hematopoietic and endothelial lineages
P Georgiades et al.
GENESIS (2002)
Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera
S Hermouet et al.
CYTOKINE (2002)
Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study
DP Steensma et al.
BLOOD (2002)
Share Paper
